Home
Live Updates
Journey Ends for Upifitamab Rilsodotin in NaPi2b+ Platinum-Resistant Ovarian Cancer : vimarsana.com
Journey Ends for Upifitamab Rilsodotin in NaPi2b+ Platinum-Resistant Ovarian Cancer
Debra L. Richardson, MD, FACS, FACOG, expands on results with upifitamab rilsodotin in platinum-resistant high-grade serous ovarian cancer.
Related Keywords
University Of Oklahoma ,
Oklahoma ,
United States ,
Oklahoma City ,
Debral Richardson ,
,
Phasei Program ,
Ou Health ,
Stephenson Cancer Center ,
University Of Oklahoma Ou College Medicine ,
Gynecologic Oncology ,
D ,
Acs ,
Iacog ,
Upifitamab Rilsodotin ,
Platinum Resistant High Grade Serous Ovarian Cancer ,
The University Of Oklahoma College Medicine ,
vimarsana.com © 2020. All Rights Reserved.